Clinical Trial: Clinical Study to Evaluate the Efficacy of Febuxostat in the Treatment of Conservatively Managed Intracranial Hemorrhage Patients

U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07701512) titled 'Clinical Study to Evaluate the Efficacy of Febuxostat in the Treatment of Conservatively Managed Intracranial Hemorrhage Patients' on July 08.

Brief Summary: To assess the effect of Febuxostat on clinical outcomes and biomarkers of oxidative stress and inflammation in patients with conservatively managed intracranial hemorrhage.

Study Start Date: Nov. 20, 2025

Study Type: INTERVENTIONAL

Condition: Intracranial Hemorrhage

Intervention: DRUG: Febuxostat 40 mg

Participants in this arm will receive Febuxostat at a dose of 40 mg orally once daily for a duration of three months, administered in addition to the standard traditional ...